AMPE - Ampio Pharma stock surge 33% on AP-019 Phase II study expansion to India

Ampio Pharmaceuticals (AMPE) soars 33% premarket after receiving regulatory approval to expand enrollment of its AP-019 Phase II study to India.The study will utilize inhaled Ampion to treat people suffering from respiratory distress due to COVID-19. Due to the ongoing political unrest in Israel combined with reduction in COVID cases, the Company has a made a strategic decision to discontinue the AP-019 study efforts in Israel and reallocate these resources to select regions of India and other potential territories outside U.S.The company initiated the AP-019, placebo-controlled Phase II trial, following the strong top-line results from AP-014 Phase I trial.

For further details see:

Ampio Pharma stock surge 33% on AP-019 Phase II study expansion to India